1.�й�ҽѧ��ѧԺ����ҽԺ, a. ҩ����;b. ͳ����;c. �ĵ�ͼ��,���� 100021;
2.�й�ҩ�ƴ�ѧ����ҽѧ���ٴ�ҩѧѧԺ,�Ͼ� 210009;
3.�Ĵ�ʡҽѧ��ѧԺ�Ĵ�ʡ����ҽԺҩѧ��,�ɶ� 610072
An Analysis of Incidence and Risk Factor of Acute Cardiactoxicity Associated with Anthracyclines Use in Patients with Breast Cancer
HE Fei1a, BO Ming-ming2, LIANG Xin1b, PENG Li-li1c,CHEN Min3, LI Guo-hui1a*
1a. Department of Pharmacy; 1b. Medical Statistics Office;1c. ECG Room, Cancer Hospital & Institute, Chinese Academy of Medical Science, Beijing 100021, China;
2. Clinical Pharmacy, Faculty of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China;
3. Pharmacy, Sichuan Provincial People′s Hospital, Sichuan Academy of Medical Science, Chengdu 610072, China
OBJECTIVE To assess the risk of acute cardiactoxicity associated with anthracyclines use in patients with breast cancer and investigate the influencing factors on acute cardiactoxicity.METHODS Cross-sectional analysis was carried out for 213 inpatients with breast cancer who received chemotherapy.RESULTS ECG changes occurred in 37% patients. It was estimated that the incidence of acute cardiactoxicity associated with anthracyclines was about 30%. The main risk factors of acute cardiactoxicity were previous chemotherapy or radiotherapy, relative higher age(≥55), and menopause.CONCLUSION ECG is an effective examination method for the patients who have acute cardiactoxicity reactions associated with anthracyclines. Clinical pharmacists should give more pharmaceutical care to post-menopause patients who have previously received chemotherapy or radiotherapy and are relatively old(≥55 years).
�ط�, ������, ��п, ������, ���, �����. �컷��ҩ�������ٰ�����������Եķ�����Ӱ�����صĻع����о�[J]. �й�ҩѧ��־, 2017, 52(12): 1089-1092.
HE Fei, BO Ming-ming, LIANG Xin, PENG Li-li,CHEN Min, LI Guo-hui. An Analysis of Incidence and Risk Factor of Acute Cardiactoxicity Associated with Anthracyclines Use in Patients with Breast Cancer. Chinese Pharmaceutical Journal, 2017, 52(12): 1089-1092.
CHEN M H, COLAN S D, DILLER L. Cardiovascular disease:cause of morbidity and mortality in adult survivors of childhood cancers[J]. Circ Res, 2011, 108(5):619-628.
[2]
CARVER J R, SHAPIRO C L, NG A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors:cardiac and pulmonary late effects[J]. J Clin Oncol, 2007, 25:3991-4008.
[3]
JENSEN B V. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer[J]. Semin Oncol, 2006,33(3 suppl 8):15-21.
[4]
WALLACE K B. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis[J]. Cardiovasc Toxicol, 2007, 7:101-107.
[5]
YEH E T, TONG A T, LENIHAN D J, et al. Cardiovascular complications of cancer therapy:diagnosis, pathogenesis, and management[J]. Circulation, 2004,109(25):3122-3131.
[6]
KEEFE D L. Anthracycline-Induced cardiomyopathy[J]. Semin Oncol, 2001, 28(4 suppl 12):2-7.
[7]
HERRMANN J, LERMAN A. Evaluation and management of patients with heart disease and cancer:cardio-oncology[J]. Mayo Clin Proc(�ٴ�����ѧ��־), 2014, 89(9):1287-1306.
[8]
Chinese Society of Clinical Oncology, Blood Institude of Chinese Medical Association. 2013 Guidlines for the prevention and treatment of anthracycline cardiotoxicity[J]. Chin Clin Oncol(�ٴ�����ѧ��־), 2013,18(10):925-934.
[9]
PIZZINO F,VIZZARI G,BOMZER C A,et al. Diagnosis of chemotherapy-induced cardiotoxicity [J]. J Patient Cent Res Rev,2014,1(3):121-127.
[10]
STEWART F A, SEEMANN I, HOVING S, et al. Understanding radiation-induced cardiovascular damage and strategies for intervention[J]. Clin Oncol, 2013, 25(10):617-624.
[11]
ZHANG R S, CHEN L L, LIN L, et al. Effects of the menopause on cardiac function in healthy women[J]. Chin J Dract Gynecol Obster(�й�ʵ�ø����������־),2000,16(2):99-101.
2017, Vol. 52 
